Barbara Sjouke

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1515399/publications.pdf

Version: 2024-02-01

30	1,753	394421 19	454955 30
papers	citations	h-index	g-index

30	30	30	2491
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical characteristics of primary carnitine deficiency: A structured review using a caseâ€byâ€case approach. Journal of Inherited Metabolic Disease, 2022, 45, 386-405.	3.6	18
2	Biochemical and imaging parameters in acid sphingomyelinase deficiency: Potential utility as biomarkers. Molecular Genetics and Metabolism, 2020, 130, 16-26.	1.1	15
3	The clinical and molecular diversity of homozygous familial hypercholesterolemia in children: Results from the GeneTics of clinical homozygous hypercholesterolemia (GoTCHA) study. Journal of Clinical Lipidology, 2019, 13, 272-278.	1.5	7
4	Autosomal Recessive Hypercholesterolemia. Journal of the American College of Cardiology, 2018, 71, 279-288.	2.8	38
5	Screening for lysosomal acid lipase deficiency: A retrospective data mining study and evaluation of screening criteria. Atherosclerosis, 2018, 278, 174-179.	0.8	2
6	Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 507-514.	1.5	19
7	Lipoprotein(a) Improves Cardiovascular Risk PredictionÂBased on Established Risk Algorithms. Journal of the American College of Cardiology, 2017, 69, 1513-1515.	2.8	31
8	Effects of Supra-Physiological Levothyroxine Dosages on Liver Parameters, Lipids and Lipoproteins in Healthy Volunteers: A Randomized Controlled Crossover Study. Scientific Reports, 2017, 7, 14174.	3.3	4
9	Serum Lipids and Lipoproteins During Uncomplicated Malaria: A Cohort Study in LambarÃ©nÃ©, Gabon. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1205-1214.	1.4	11
10	Children with hypercholesterolemia of unknown cause: Value of genetic risk scores. Journal of Clinical Lipidology, 2016, 10, 851-859.	1.5	21
11	Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. Atherosclerosis, 2016, 248, 238-244.	0.8	50
12	Effects of mineralocorticoid receptor antagonists on the risk of thrombosis, bleeding and mortality: A systematic review and meta-analysis of randomized controlled trials. Thrombosis Research, 2016, 144, 32-39.	1.7	4
13	Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemiaâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1647-1650.	2.4	23
14	Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease. Journal of Clinical Lipidology, 2016, 10, 1462-1469.	1.5	25
15	Sequencing for LIPA mutations in patients with a clinical diagnosis of familial hypercholesterolemia. Atherosclerosis, 2016, 251, 263-265.	0.8	27
16	Retrospective analysis of cohort database: Phenotypic variability in a large dataset of patients confirmed to have homozygous familial hypercholesterolemia. Data in Brief, 2016, 7, 1458-1462.	1.0	2
17	Homozygous autosomal dominant hypercholesterolaemia. Current Opinion in Lipidology, 2015, 26, 200-209.	2.7	52
18	Screening and treatment of familial hypercholesterolemia â€“ Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014). Atherosclerosis, 2015, 241, 597-606.	0.8	34

#	Article	IF	Citations
19	Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: A European cross-sectional study. Atherosclerosis, 2015, 240, 90-97.	0.8	43
20	Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circulation: Cardiovascular Genetics, 2015, 8, 823-831.	5.1	90
21	Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotypeâ€“phenotype relationship, and clinical outcome. European Heart Journal, 2015, 36, 560-565.	2.2	366
22	Nonpharmacological Lipoprotein Apheresis Reduces Arterial Inflammation inÂFamilial Hypercholesterolemia. Journal of the American College of Cardiology, 2014, 64, 1418-1426.	2.8	90
23	Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Diabetes and Endocrinology,the, 2014, 2, 455-463.	11.4	84
24	Is mipomersen ready for clinical implementation? A transatlantic dilemma. Current Opinion in Lipidology, 2013, 24, 301-306.	2.7	19
25	Exome Sequencing and Directed Clinical Phenotyping Diagnose Cholesterol Ester Storage Disease Presenting as Autosomal Recessive Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2909-2914.	2.4	87
26	Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 3058-3065.	2.4	146
27	The role of antibiotic prophylaxis in endoscopic retrograde cholangiopancreatography; a retrospective single-center evaluation. Scandinavian Journal of Gastroenterology, 2012, 47, 245-250.	1.5	14
28	The PCSK9 decade. Journal of Lipid Research, 2012, 53, 2515-2524.	4.2	355
29	Genetic variation inAPOB,PCSK9, andANGPTL3in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels. Human Mutation, 2012, 33, 448-455.	2.5	36
30	Familial Hypercholesterolemia: Present and Future Management. Current Cardiology Reports, 2011, 13, 527-536.	2.9	40